The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
https://pubmed.ncbi.nlm.nih.gov/38758239/
京都大学 島津 裕 Cancer Immunology, Immunotherapy.2024 May 17;73(7):135.
![](https://myeloma.jp/wp-content/themes/cocoon-master/screenshot.jpg)
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
https://pubmed.ncbi.nlm.nih.gov/38758239/